Glaxosmithkline Pharmaceuticals Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹45.5K Cr
GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026. GSK India aims to grow above the Indian Pharmaceutical Market (IPM) growth of 8-9% for FY2026.
From Glaxosmithkline Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,902
Market Cap
₹45.5K Cr
P/E Ratio
43.3
How does Glaxosmithkline Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Glaxosmithkline Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹995 Cr, net profit ₹278 Cr.
Full financials →📊 Revenue & Sales Performance
- →GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026.
- →The aspiration for double-digit growth remains firmly in place.
- →Growth strategy is primarily volume-led, especially in the general medicines portfolio, with volume growth recorded at around 8% recently.
- →Price hikes are considered a supplementary lever but not the main growth driver, mainly due to price controls on over half the portfolio.
- →Specialty segments, including oncology and vaccines (e.g., Shingrix), are expected to contribute significantly to future growth.
- →Investments continue in digital and omni-channel outreach to expand healthcare practitioner coverage, increasing touchpoints by over 40%.
- →New innovative product launches, especially in oncology (e.g., Zejula, Jemperli) and respiratory areas, are anticipated to fuel growth.
- →Sustainable EBITDA margins are targeted alongside top-line growth, balancing investment in new launches and operational efficiency.
📈 Profitability & Margins
- →GSK India aims to grow above the Indian Pharmaceutical Market (IPM) growth of 8-9% for FY2026.
- →The focus remains on volume-led growth rather than relying heavily on price increases.
- →Oncology and specialty portfolios are expected to be new growth platforms alongside general medicines and vaccines.
- →EBITDA margins have improved significantly, now around 31%, and the company aims to sustain these margins.
- →No specific forward guidance on EBITDA margins or EPS was provided, but the management intends to maintain profitability while investing in growth areas.
- →Continued strong volume growth supports earnings expansion, with margin improvements driven by operating leverage and cost optimization.
- →The company plans to accelerate innovative asset launches to fuel future revenue and profit growth.
- →Management's aspiration for double-digit growth still holds, aligned with above-market growth ambitions.
🏗️ Capital Expenditure Plans
- →The company is investing significantly in oncology market development, including recruitment of a new oncology business head and expanding the medical team.
- →There is continued focus on accelerating the launch of innovative assets from the global pipeline, as evidenced by ongoing clinical trials (19 global trials in oncology, hepatology, etc.) and planned launches of oncology products like Zejula and Jemperli.
- →Manufacturing capability is maintained and leveraged with a state-of-the-art facility in Nashik that supplies significant volumes and serves WHO programs.
- →Emphasis remains on sustaining and improving margins while investing in new growth platforms such as vaccines (e.g., Shingrix) and specialty medicines.
- →Digital and omni-channel marketing investments continue to expand reach and prescription growth.
- →While no explicit standalone capex figure is disclosed, operational investments are directed toward clinical development, market expansion, manufacturing, and digital transformation to support future growth.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising activities through debt or equity.
- →The company highlights a strong balance sheet with an estimated cash position close to INR 2,500 crores and zero debt.
- →There is no indication of any fundraising needs; instead, focus is on sustaining margins and investing internally, especially in new innovative asset launches.
- →The management emphasizes maintaining healthy operating leverage and cash conversion, signaling no immediate requirement for external capital raise.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Glaxosmi. Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q4 FY25 results?
GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026. GSK India aims to grow above the Indian Pharmaceutical Market (IPM) growth of 8-9% for FY2026.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 43.3 with a market cap of ₹45,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
The company is investing significantly in oncology market development, including recruitment of a new oncology business head and expanding the medical team.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.